GeneSuites is a development and strategic partner that removes barriers for life science companies beginning phase II-III clinical trials or seeking to enter the U.S. market. In partnership with industry experts and validated by third-party reviewers, GeneSuites was founded in 2020 with a novel solution to address the imbalance in supply and demand for biomanufacturing capacity while offering critical PD and cGMP manufacturing advantages. 

We specialize in advancing biomanufacturing strategies from beginning to end.